Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to discuss 2 cheap quality stocks to consider in this heated market.

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor16 Nov 2025, 18:57 UTC
Video preview for Friends! In this video, I'm going to discuss 2 cheap quality stocks to consider in this heated market.
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
1
Canonical correct result
Failed
1
Canonical failed result
Resolved success
50%
Open and excluded signals omitted
Source overview

AI-generated source summary

The video presents a fundamental analysis of META and AMZN stocks, particularly focusing on META. It highlights that during market rallies, investors often overlook risks, while during sell-offs, they ignore opportunities. META is deemed inexpensive at 20 times earnings, compared to Google at 26, and Tesla at 197. It is over a trillion-dollar company still growing, with revenues up by 26% quarterly. Although the expectation is to go lower and if AI fears continue the stock may go to $550. The company has access to 3.5 billion users daily. For AMZN target is at $220. Both the robotics and the growing square footage is helping margins.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.